

19/05/2022

Dear Requester,

FOI 1341

Thank you for your Freedom of Information request which was received within the Trust.
Please note, this is a cross-site response for Bedford site and Luton site.

You asked:

1. How many patients has your trust treated in the past 3 months for the following conditions:
 - Chronic Lymphocytic Leukaemia (CLL) **27**
 - Mantle Cell Lymphoma (MCL) **1-5**
 - In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.

2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:
 - BR (bendamustine + rituximab) **0**
 - Calquence (acalabrutinib) **10**
 - FCR (fludarabine + cyclophosphamide + rituximab) **0**
 - Gazyva (obinutuzumab) + chlorambucil **0**
 - Imbruvica (ibrutinib) **11**
 - Venclexta (venetoclax) **1-5**
 - Venclexta (venetoclax) + Gazyva (obinutuzumab) **1-5**
 - Venclexta (venetoclax) + rituximab **1-5**
 - Zydelig (idelalisib) + rituximab **0**
 - Any other systemic anti-cancer therapy **BOSUTINIB - 1-5**

3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:
 - BR (bendamustine + rituximab) **1-5**
 - Imbruvica (ibrutinib) **1-5**
 - Imbruvica (ibrutinib) + rituximab **0**
 - R-BAC (rituximab, bendamustine and cytarabine) **0**
 - R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) **0**
 - Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) **0**
 - Velcade (bortezomib) + chemotherapy **0**

- Any other systemic anti-cancer therapy 1-5
 - Stem cell transplant 0
 - Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells 0
4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part? No
5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part? No

This information is provided for your personal use and is the property of Bedfordshire Hospitals NHS Trust and subject to any existing Intellectual Property and Database Rights. Any commercial application or use of this information may be subject to the provisions of the Re-use of Public Sector Information Regulations 2015 (RPSI). This means that if you wish to re-use the information provided for commercial purposes for any reason you must ask the Trust for permission to do so.

Please note that the Trust has a formal internal review and complaints process which is managed by the Information Governance Manager/Data Protection Officer. Should you have any concerns with our response, you can make a formal request for an internal review. Requests *for internal review* should be submitted within three months of the date of receipt of the response to your original letter, and should be addressed to: dataprotectionofficer@ldh.nhs.uk. This option is available to you for up to three calendar months from the date your response was issued.

If you are not satisfied with the Trust review under the Freedom of Information Act 2000 you may apply directly to the Information Commissioners Officer (ICO) for a review of your appeal decision. The ICO can be contacted at: ICO, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF www.ico.org.uk

Yours sincerely,

FOI Officer

Bedfordshire Hospitals NHS Foundation Trust